Drugs / NaMFP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01128946 | Nov 2009 → Mar 2010 | dental caries | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT07471477 Background | Mar → Jun 2026 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT07276672 Comparator | Nov 2025 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT06486974 Comparator | Sep → Nov 2024 | tooth disorder | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT00708097 Comparator | Apr → Jul 2008 | dental caries | GlaxoSmithKline | Completed | Missed primary |
| — | NCT06140745 Comparator | Oct 2020 → Feb 2021 | dental caries | Procter and Gamble | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Na MFP | “0.76% Na MFP” NCT07276672 ↗ |
| Known as | sodium monofluorophosphate | “Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.” NCT01128946 ↗ |